MedTrace Logo

Adrenomedullin and Outcome in Severe Sepsis and Septic Shock

NCT02393781 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 596

Last updated 2016-06-06

No results posted yet for this study

Summary

The aim of this prospective study is to assess the prognostic value of bioactive plasma adrenomedullin (ADM) in 600 patients with severe sepsis or septic shock in an international multicenter study and to validate the findings concerning the association of ADM concentration and the use of vasopressor therapy, organ failure and outcome.

Conditions

  • Severe Sepsis
  • Septic Shock

Sponsors & Collaborators

  • Fondation Transplantation_EDDH

    collaborator UNKNOWN

  • Hopital Lariboisière

    collaborator OTHER

  • Cliniques universitaires Saint-Luc- Université Catholique de Louvain

    collaborator OTHER

  • Sphingotec GmbH

    lead INDUSTRY

Principal Investigators

  • Alexandre Mebazaa, Pr · Hôpital Lariboisière, France

  • Pierre François Laterre, Pr · Clinique Universitaire St Luc, Belgique

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-30
Primary Completion
2016-05-31
Completion
2016-06-30

Countries

  • Belgium
  • France
  • Germany
  • Italy
  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02393781 on ClinicalTrials.gov